Authorized purpose: Triage and notification of suspected hemispheric subdural hemorrhage (SDH) on non-enhanced head CT, in parallel with standard-of-care interpretation; not diagnostic.
Clinical role
Parallel notification-only triage/prioritization for suspected hemispheric SDH without image-region marking or alteration of the original study.
Images and patients
CT/CTA · Head, specifically hemispheric subdural space
Key limitation
Keep in mind: Subdural hygroma, empyema, and effusion mimics were not included in validation; excessive motion can make scans technically inadequate; intravenous contrast may cause false-positive suspected SDH. Email/mobile previews are compressed and non-diagnostic, and clinicians must view non-compressed images on a diagnostic viewer; the device is not stand-alone or diagnostic.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Triage and notification of suspected hemispheric subdural hemorrhage (SDH) on non-enhanced head CT, in parallel with standard-of-care interpretation; not diagnostic.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head, specifically hemispheric subdural space Input: Non-enhanced/non-contrast head CT images for patients older than 21 undergoing screening for acute or chronic hemispheric SDH; validation was against hemispheric SDH of at least 1 mL.
Who uses it?Intended users: Trained radiologists and notified clinicians.
What does the software produce?Output: A priority notification indicating suspected hemispheric SDH with compressed preview images for informational use; the Rapid Platform provides DICOM processing, imaging output, and notification, while full images remain for diagnostic review.
What is its most important limitation?Key limitation: Subdural hygroma, empyema, and effusion mimics were not included in validation; excessive motion can make scans technically inadequate; intravenous contrast may cause false-positive suspected SDH. Email/mobile previews are compressed and non-diagnostic, and clinicians must view non-compressed images on a diagnostic viewer; the device is not stand-alone or diagnostic.
Clinical takeaway. Clinical role: Triage and notification of suspected hemispheric subdural hemorrhage (SDH) on non-enhanced head CT, in parallel with standard-of-care interpretation; not diagnostic.
Evidence takeaway. Evidence from the reviewed source record: FDA packet: retrospective, blinded, multicenter, multinational study of 310 samples (147 positive, 163 negative) with three expert neuroradiologists establishing truth. Default sensitivity was 0.924 (95% CI 0.871-0.956), specificity 0.987 (95% CI 0.95477-0.996), and ROC AUC 0.995 (0.986-1.0). The secondary notification-time endpoint reported a median processing time of 45 seconds, with a 33-107 second range; gender, age, subtype, volume, slice-thickness, manufacturer, and site subgroup tables are separate.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Triage and notification of suspected hemispheric subdural hemorrhage (SDH) on non-enhanced head CT, in parallel with standard-of-care interpretation; not diagnostic.
Non-enhanced/non-contrast head CT images for patients older than 21 undergoing screening for acute or chronic hemispheric SDH; validation was against hemispheric SDH of at least 1 mL.
A priority notification indicating suspected hemispheric SDH with compressed preview images for informational use; the Rapid Platform provides DICOM processing, imaging output, and notification, while full images remain for diagnostic review.
Subdural hygroma, empyema, and effusion mimics were not included in validation; excessive motion can make scans technically inadequate; intravenous contrast may cause false-positive suspected SDH. Email/mobile previews are compressed and non-diagnostic, and clinicians must view non-compressed images on a diagnostic viewer; the device is not stand-alone or diagnostic.
FDA packet: retrospective, blinded, multicenter, multinational study of 310 samples (147 positive, 163 negative) with three expert neuroradiologists establishing truth. Default sensitivity was 0.924 (95% CI 0.871-0.956), specificity 0.987 (95% CI 0.95477-0.996), and ROC AUC 0.995 (0.986-1.0). The secondary notification-time endpoint reported a median processing time of 45 seconds, with a 33-107 second range; gender, age, subtype, volume, slice-thickness, manufacturer, and site subgroup tables are separate.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet: retrospective, blinded, multicenter, multinational study of 310 samples (147 positive, 163 negative) with three expert neuroradiologists establishing truth. Default sensitivity was 0.924 (95% CI 0.871-0.956), specificity 0.987 (95% CI 0.95477-0.996), and ROC AUC 0.995 (0.986-1.0). The secondary notification-time endpoint reported a median processing time of 45 seconds, with a 33-107 second range; gender, age, subtype, volume, slice-thickness, manufacturer, and site subgroup tables are separate.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Rapid SDH regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K232436
Samplen=310
IndependenceIndependence not established
K232436
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232436. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Non-enhanced/non-contrast head CT images for patients older than 21 undergoing screening for acute or chronic hemispheric SDH; validation was against hemispheric SDH of at least 1 mL.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA packet describes the Rapid SDH module within the integrated Rapid Platform, with DICOM processing, job management, image execution/output, and server or standalone desktop operation; PACS/workstation review and email/mobile previews are described, but exact local interfaces are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Returned objects
Source context, not route validation: A priority notification indicating suspected hemispheric SDH with compressed preview images for informational use; the Rapid Platform provides DICOM processing, imaging output, and notification, while full images remain for diagnostic review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A priority notification indicating suspected hemispheric SDH with compressed preview images for informational use; the Rapid Platform provides DICOM processing, imaging output, and notification, while full images remain for diagnostic review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA packet describes the Rapid SDH module within the integrated Rapid Platform, with DICOM processing, job management, image execution/output, and server or standalone desktop operation; PACS/workstation review and email/mobile previews are described, but exact local interfaces are not established.
RapidAI's current platform security and compliance one-pager states that its portfolio uses encryption at rest and in transit, role-based access control, monitoring/logging and listed HIPAA, GDPR, ISO 13485, ISO 27001, ISO 27701 and SOC 2 Type 1 claims.
Vendor-wide
Checked 2026-10-25
This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.
RapidAI's security and compliance one-pager (Rev 8, published by iSchemaView, Inc.) states continuous infrastructure monitoring and system telemetry to detect operational anomalies in real time, plus a formal incident response and escalation framework with defined communication protocols.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. No certificate or audit report was read; the one-pager names the RapidAI platform generally and does not scope these commitments to any specific product release; exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor security document, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K232436 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.
Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Authorized purpose: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.
Modality
CT/CTA
Anatomy
Brain/head, including intracranial ICA and M1 for LVO and intracranial hemorrhage findings
Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.